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Background/Aims: Endoscopic ultrasound (EUS)-guided 
fine needle aspiration (FNA; EUS-FNA) allows for diagnostic 
tissue specimens from various regions to be analyzed. How-
ever, diagnosing recurrent pancreaticobiliary cancer after 
surgery is sometimes difficult. We evaluated the efficacy of 
EUS-FNA in the diagnosis of local recurrence of pancreatico-
biliary cancer and analyzed the factors associated with false-
negative results. Methods: Fifty-one consecutive patients 
who underwent EUS-FNA due to suspected recurrence of 
pancreaticobiliary cancer after surgery in an academic cen-
ter were retrospectively analyzed. The criteria for EUS-FNA 
were a resected margin or remnant pancreas mass, round 
swollen lymph node (≥10 mm in diameter), and soft-tissue 
enhancement around a major artery. Patients with suspected 
liver metastasis or malignant ascites were excluded. Results: 
Thirty-nine of the 51 patients had pancreatic cancer; the 
remaining 12 had biliary cancer. The target sites for EUS-FNA 
were the soft tissue around a major artery (n=22, 43%), the 
resected margin or remnant pancreas (n=12, 24%), and the 
lymph nodes (n=17, 33%). The median size of the suspected 
recurrent lesions was 15 mm (range, 8 to 40 mm). The over-
all sensitivity, specificity and accuracy of EUS-FNA for the 
diagnosis of recurrence was 84% (32/38), 100% (13/13), 
and 88% (45/51), respectively. FNA of the soft tissue around 
major arteries (odds ratio, 8.23; 95% confidence interval, 1.2 
to 166.7; p=0.033) was significantly associated with a false-
negative diagnosis in the multivariate analysis. Conclusions: 
EUS-FNA is useful for diagnosing recurrent cancer, even after 
pancreaticobiliary surgery. The diagnoses of recurrence at 
soft-tissue sites should be interpreted with caution. (Gut 
Liver 2020;14:652-658)
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INTRODUCTION
The prognosis of pancreaticobiliary cancer is one of the poor-
est among all malignancies. The 5-year survival rates among all 
patients with pancreatic or biliary cancer are less than 6% and 
14%, respectively.1 Complete surgical resection is the only cura-
tive treatment for this disease and is an independent predictor 
of postoperative survival. However, even after resection with a 
negative margin, the vast majority of cancers recur, either as 
distant metastases or local disease.2-7
Endoscopic ultrasound (EUS)-guided fine needle aspiration 
(FNA; EUS-FNA) is a very sensitive tool for the initial diagnosis 
of pancreaticobiliary cancer. The advantage of EUS-FNA in the 
diagnosis of pancreaticobiliary disease is the ability to perform 
percutaneous biopsy from a region that is often otherwise inac-
cessible to provide a tissue diagnosis. The sensitivity and speci-
ficity of EUS-FNA in the diagnosis of pancreaticobiliary cancer 
are reported to be 85% and 98%, respectively, for pancreatic 
cancer,8 and 91% and 89% for biliary cancer.9,10 However, the 
accuracy of an EUS-FNA in the diagnosis of recurrent cancer is 
lower than that at its initial diagnosis.7 The problems of EUS-
FNA after pancreaticobiliary surgery (e.g., pancreaticoduodenec-
tomy; PD), include difficulty in visualizing the target lesion and 
securing a safe puncture route. Thus, the aspirated specimen 
is sometimes insufficient for a definite pathological diagnosis. 
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Furthermore, pancreaticobiliary cancer sometimes recurs in the 
nerve plexus around a major artery.
To the best of the authors’ knowledge, there has only been 
one report about EUS-FNA for local recurrence after pancreatic 
cancer surgery,7 and there have been no reports about EUS-FNA 
for the diagnosis of recurrent cancer after pancreaticobiliary 
surgery in a large study population. Considering the efficacy of 
recent chemotherapy for pancreaticobiliary cancer, it is useful 
to diagnose recurrent cancer at an early stage. In this study, we 
evaluated the usefulness of EUS-FNA in the diagnosis of sus-
pected cancer recurrence after pancreaticobiliary surgery, and 
also analyzed the risk factors for a false-negative diagnosis.
MATERIALS AND METHODS
1. Patients
The criteria for performing EUS-FNA were as follows: the 
appearance of a mass in the resected margin or remnant pan-
creas, a round swollen lymph node with a diameter of ≥10 mm, 
and enhancement of the soft tissue around a major artery (e.g., 
celiac artery, superior mesenteric artery, and common hepatic 
artery) (Figs 1-3). Patients with suspected liver metastasis or 
malignant ascites or recurrence at the resected margin after R1 
resection were excluded. During the study period (January 2006 
to March 2018), 57 patients were considered for EUS-FNA due 
to suspected tumor recurrence after attempted curative resection 
for pancreaticobiliary cancer at our institution. Among them, 
the target lesion could not be observed in one patient, and EUS-
FNA was technically difficult to perform in three patients (due 
to an interruption of the vessels, target: the presence of soft tis-
sue around the superior mesenteric artery: 2, and the occurrence 
of a lymph nodule around aorta: 1). The technical success rate 
of EUS-FNA was 93% (53/57). Of the 53 patients who under-
went EUS-FNA successfully, two experienced recurrence at the 
Fig. 1. (A) Computed tomography 
showing a mass in the resected mar-
gin of the pancreas after distal pan-
createctomy (arrow). (B) Endoscopic 
ultrasound-guided fine needle aspi-
ration of a mass (arrow).
PV, portal vein.
Fig. 2. (A) Computed tomography 
showing a round swollen lymph 
node (arrow) around the aorta after 
subtotal stomach-preserving pancre-
aticoduodenectomy. (B) Endoscopic 
ultrasound-guided fine needle aspi-
ration of a lymph node (arrow). 
Fig. 3. (A) Computed tomography 
showing soft tissue around a major 
artery (arrow). (B) Endoscopic ultra-
sound-guided fine needle aspiration 
of soft tissue (arrows). 
CA, celiac artery. 
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resected margin after R1 resection. Ultimately, 51 patients were 
retrospectively analyzed in this study (Fig. 4). 
One of the following surgical procedures was applied in all 
cases: classical PD, subtotal stomach-preserving pancreatico-
duodenectomy, distal pancreatectomy, total pancreatectomy, 
distal pancreatectomy with en bloc celiac axis resection, hepatic 
resection and hepaticojejunostomy, or hepatopancreaticoduo-
denectomy. The resected cancers were pathologically classified 
according to the International Union against Cancer TNM Clas-
sification of Malignant Tumors 6th edition.
This study was approved by our institution’s review board 
for human research and was conducted in accordance with the 
Declaration of Helsinki (Okayama University Graduate School of 
Medicine, Dentistry and Pharmaceutical Science and Okayama 
University Hospital, Ethics Committee, approval number: 1805-
024). Written informed consent was obtained from all subjects.
2. EUS-FNA techniques
We performed EUS using a convex linear-array endoscope 
(GF-UCT260 or GF-UCT240; Olympus Medical Systems, Tokyo, 
Japan and EG-580UT: Fujifilm Corp, Tokyo, Japan) connected 
to an ultrasound device (Prosound SSD-α10; Hitachi Aloka, 
Tokyo, Japan, EU-ME1 or EU-ME2 PREMIER PLUS; Olympus, 
SU-1 ultrasound processor; Fujifilm Corp). EUS-FNA was per-
formed with a 22- and/or 25-gauge needle (EZ-Shot 3; Olympus 
Medical Systems; Acquire, Boston Scientific Corp., Marlbor-
ough, MA, USA; EchoTip ProCore, Cook Medical, Bloomington, 
IN, USA; SonoTip II, Medi-Globe GmbH, Rohrdorf, Germany; 
Expect, Boston Scientific Corp.).
EUS-FNA was repeated until sufficient sampling had been 
performed for rapid on-site evaluation or until the endoscopist 
believed that further sampling was unlikely to increase the 
amount of tissue.
3. The pathological diagnosis
All aspirated samples were expressed onto a glass slide by 
reinsertion of the stylet into the FNA needle. The aspirated 
samples were divided into a white tissue part for histological 
evaluation and the remaining portion was used for a cytological 
evaluation. Two smear preparations of the samples were made 
for each cytological evaluation: One slide was subjected to 
modified Giemsa staining for rapid on-site evaluation, whereas 
the other slide was alcohol-fixed and subjected to Papanicolaou 
staining. A definitive cytohistopathological diagnosis was made 
by two pathologists. For EUS-FNA samples, specimens were 
classified as having no malignancy, atypical cells, malignancy, 
or being inadequate if representative material was not present. 
When pathological specimens did not disclose any definitive 
malignancy or were inadequate, clinical and/or imaging follow-
up examinations were performed every 2 to 3 months, and 
the definitive diagnosis of benign was decided after at least 6 
months of follow-up. 
4. Statistical analyses
Continuous variables were expressed as the median and 
range, or interquartile range (IQR). Categorical variables were 
analyzed using the chi-square test. The Student t-test was used 
to compare continuous variables. Factors with p-values <0.20 
using the forward method were considered to be potential risk 
factors for a false-negative diagnosis and were analyzed in a 
multiple logistic regression model. Odds ratios and 95% confi-
dence intervals were calculated. Two-tailed p-values <0.05 were 
considered to indicate statistical significance. All analyses were 
performed using the JMP Pro 12 software program (SAS Insti-
tute, Cary, NC, USA).
RESULTS
1. Patient characteristics
Table 1 summarizes the characteristics of 51 patients who 
underwent EUS-FNA due to suspected recurrence of pancre-
aticobiliary cancer after surgical resection. The median age of 
the patients was 66 years (range, 50 to 84 years). The primary 
diseases were pancreatic cancer in 39 patients (76%) and bili-
ary cancer in 12 patients (24%). A total of 47 and four patients 
underwent R0 and R1 resection, respectively. Forty-six patients 
(90%) received adjuvant therapy with S-1, and no patients 
received radiation therapy after surgery. The median value of 
Fig. 4. The flowchart of this study. 
EUS-FNA, endoscopic ultrasound-
guided fine needle aspiration. 
57 Patients were attempted EUS-FNA for suspected recurrence lesions
(excluding liver metastasis or malignant ascites)
53 Patients were successfully performed EUS-FNA
51 Patients were analyzed
Screening failure (n=1)
Technical failure (n=3)
Recurrence at resected margin
after R1 resection (n=2)
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serum carbohydrate antigen 19-9 (CA19-9) at EUS-FNA was 
141 U/mL (IQR, 22 to 303 U/mL), and 26 patients (51%) showed 
an abnormal level of CA19-9. The median interval between 
the operation and EUS-FNA was 13.0 months (IQR, 7.3 to 31.9 
months). The median flow-up period after EUS-FNA for sites of 
recurrence and the initial diagnosis were 16.1 months (IQR, 7.9 
to 25.5 months) and 34.7 months (IQR, 22.3 to 56.7 months).
2. EUS-FNA for suspected recurrent lesions
Table 2 shows the results of EUS-FNA for 51 patients with 
suspected recurrence. The median size of the suspected recur-
rent lesion, excluding the soft tissue around a major artery, was 
15 mm (range, 8 to 40 mm). The target site for EUS-FNA was 
the soft tissue around a major artery in 22 patients (43%), the 
resected margin in seven patients (14%), the remnant pancreas 
in five patients (10%), and the lymph nodes in 17 patients (33%). 
Among patients who underwent EUS-FNA at the soft tissue 
around the artery, six (27%) showed an unclear low-echoic le-
sion on EUS imaging. The median number of needle passes was 
2 (range, 1 to 7). The needle size used for FNA was 22-gauge in 
36 cases (70%) and 25-gauge in 15 cases (30%). 
3. The pathological diagnosis of EUS-FNA samples
For 51 patients, the final diagnosis after clinical follow-up 
was recurrent pancreaticobiliary cancer in 38 cases and non-
recurrence of pancreaticobiliary cancer in 13 cases. Of the 38 
samples from recurrent cases, 32 samples were positive for 
malignancy and six were benign (atypical cells, n=2; no malig-
nancy, n=2; inadequate, n=2). Of the six patients in which the 
pathological diagnosis was benign, three patients underwent 
EUS-FNA of the same lesion again within 3 months, and all 
samples were pathologically malignant (soft tissue, n=2; lymph 
node, n=1). The other three patients developed recurrent dis-
ease as metastasis to the liver and peritoneum on computed 
tomography (CT) during clinical follow-up (soft tissue, n=3). In 
comparison, among the 13 non-recurrent samples, six samples 
were non-malignant, three samples were atypical, and four were 
inadequate. No patients developed recurrent disease during the 
follow-up period after EUS-FNA (median, 25.3 months; IQR, 
15.2 to 47.8 months).
4. Diagnostic ability of EUS-FNA
The sensitivity, specificity, and overall accuracy were 84% 
(32/38), 100% (13/13), and 88% (45/51), respectively. According 
to the disease, the sensitivity, specificity and overall accuracy 
were 86% (25/29), 100% (10/10), and 90% (35/39) in pancreatic 
cancer and 78% (7/9), 100% (3/3), and 83% (10/12) in biliary 
cancer, respectively. According to the site of the EUS-FNA, the 
sensitivity, and accuracy were as follows: soft tissue around a 
Table 1. Patient Characteristics (n=51)
Parameter Value
Age, median (range), yr 66 (50–84)
Male sex 28 (55)
Diseases
   Pancreatic cancer 39 (76)
   Biliary cancer 12 (24)
      BDCa/GBCa/PVCa 10/1/1
Surgical method
   SSPPD/PD 28 (55)
   DP 12 (25)
   DP-CAR 3 (5)
   TP 1 (2)
   HR+HJ 5 (9)
   HPD 2 (4)
Residual tumor
   R0/1 47 (92)/4 (8)
Adjuvant chemotherapy 46 (90)
Serum CA19-9 at EUS-FNA, U/mL 141 (22–303)
Patients with CA19-9 value >40 U/mL 26 (51)
Interval between operation and EUS-FNA, mo 13.0 (7.3–31.9)
Follow-up period after EUS-FNA, mo 16.1 (7.9–25.5)
Follow-up after initial diagnosis, mo 34.7 (22.3–56.7)
Data are presented as number (%) or median (interquartile range).
BDCa, bile duct cancer; GBCa, gall bladder cancer; PVCa, papilla of 
Vater cancer; SSPPD, subtotal stomach-preserving pancreaticoduode-
nectomy; PD, pancreaticoduodenectomy; DP, distal pancreatectomy; 
DP-CAR, distal pancreatectomy with en bloc celiac axis resection; 
TP, total pancreatectomy; HR, hepatic resection; HJ, hepaticojejunos-
tomy; HPD, hepatopancreaticoduodenectomy; CA19-9, carbohydrate 
antigen 19-9; EUS-FNA, endoscopic ultrasound-guided fine needle 
aspiration.
Table 2. EUS-FNA for Suspected Recurrent Lesions (n=51)
Parameter Value
Size of suspected recurrent lesion, mm* 15 (8–40)
FNA site of suspected recurrence
   Soft tissue around artery 22 (43)
      CA/SMA/CHA 10/7/5
   Resected margin 7 (14)
   Remnant pancreas 5 (10)
   Lymph node 17 (33)
      Around aorta/stomach/portal vein 7/6/4
No. of needle passes 2 (1–7)
Selected FNA needle gauge
   22 36 (70)
   25 15 (30)
Data are presented as median (range) or number (%).
EUS-FNA, endoscopic ultrasound-guided fine needle aspiration; CA, 
celiac artery; SMA, superior mesenteric artery; CHA, common hepatic 
artery.
*Soft-tissue lesions excluded.
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major artery: 55% (6/11) and 77% (17/22); remnant or margin 
of the pancreas: 100% (12/12) and 100% (12/12); and lymph 
node: 93% (14/15) and 94% (16/17), respectively (Table 3). In 
the analysis of the soft tissue around the artery, the accuracy 
in patients with clear and unclear low-echoic masses were 81% 
(13/16) and 67% (4/6), respectively (p=0.47).
5. Analyses of the risk factors for a false-negative diagnosis
In the analysis of the risk factors for a false-negative diag-
nosis, surgery with stomach resection, and soft tissue around a 
major artery were identified as potential factors (p<0.2) in uni-
variate analyses. Multiple logistic regression revealed that soft 
tissue around a major artery (odds ratio, 8.23; 95% confidence 
interval, 1.2 to 166.7; p=0.033) was a significant risk factor for 
a false-negative diagnosis (Table 4).
DISCUSSION
This study was the first report to evaluate the diagnostic abil-
ity of EUS-FNA in the detection of recurrence after pancreati-
cobiliary surgery in a large cohort and with a sufficient follow-
up period (median flow-up period after EUS-FNA for recurrence 
sites was 16.1 months). The overall sensitivity, specificity and 
accuracy of EUS-FNA in the diagnosis of recurrence were 84% 
(32/38), 100% (13/13), and 88% (45/51), respectively. EUS-FNA 
is useful for diagnosing the recurrence of cancer, even after 
pancreaticobiliary surgery. We also analyzed the factors associ-
ated with a false-negative diagnosis, and FNA of the soft tissue 
around major arteries (odds ratio, 8.23; 95% confidence interval, 
1.2 to 166.7; p=0.033) was found to be significantly associated 
with false-negative diagnoses in the multivariate analysis.
DeWitt et al.7 reported the usefulness of EUS-FNA in the di-
agnosis of 17 patients with suspected recurrence of pancreatic 
cancer: The sensitivity and accuracy of EUS-FNA ranged from 
81% to 93% and 81% to 93%, respectively. In our study, the 
overall sensitivity, and accuracy of EUS-FNA in the diagnosis of 
recurrence were 84% (32/38), and 88% (45/51), respectively. For 
limited pancreatic cancer recurrence, the sensitivity and accu-
racy of EUS-FNA in this study were 86% and 90%, respectively. 
Our results proved similar to those of past reports. EUS-FNA is 
useful for diagnosing recurrence, even after pancreaticobiliary 
surgery.
Table 3. Performance of EUS-FNA for the Diagnosis of Cancer Recurrence (n=51)
Sensitivity, % Specificity, % PPV, % NPV, % Accuracy, %
Total 84 100 100 68 88
   Pancreatic cancer 86 100 100 71 90
   Biliary cancer 78 100 100 60 83
According to recurrence site
   Soft tissue around major artery 55 100 100 69 77
   Resected margin/remnant pancreas 100 NA 100 NA 100
   Lymph nodule 93 100 100 67 94
EUS-FNA, endoscopic ultrasound-guided fine needle aspiration; PPV, positive predictive value; NPV, negative predictive value; NA, not available.
Table 4. Univariate and Multivariate Analyses of Factors Associated with False-Negative Results
Variable
No. false negatives
(n=6)
No. true positives
(n=45)
Univariate analysis Multivariate analysis
p-value OR (95% CI) p-value
Age >65 yr 3 23 0.96 - -
Male sex 4 24 0.53 - -
Biliary cancer 2 10 0.56 - -
CA19-9 >40 U/mL 2 24 0.35 - -
Adjuvant chemotherapy 6 40 0.25 - -
Surgery with stomach resection* 5 26 0.2 3.65 (0.48–75.6) 0.22
Soft-tissue around major artery 5 17 0.03 8.23 (1.2–166.7) 0.033
Use of a 22-gauge needle 4 32 0.82 - -
No. of needle passes >2 4 18 0.21 - -
OR, odds ratio; CI, confidence interval; CA19-9, carbohydrate antigen 19-9.
*Including pancreaticoduodenectomy, subtotal stomach-preserving pancreaticoduodenectomy, total pancreatectomy, and hepatopancreaticoduo-
denectomy.
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The sensitivity and accuracy, according to the site of EUS-
FNA, was as follows: the soft tissue around a major artery: 55% 
(6/11) and 77% (17/22); remnant or margin of the pancreas: 
100% (12/12) and 100% (12/12); and lymph node: 93% (14/15) 
and 94% (16/17), respectively. The diagnostic ability of EUS-
FNA was considered sufficient for recurrent disease at the 
pancreatic remnant or margin or lymph nodes. However, the 
diagnosis of soft tissue recurrence around major arteries was a 
problem. The median number of needle passes at soft tissue sites 
was 3 (rage, 1–7) times, which was significantly greater in com-
parison to other sites (2 [rage, 1–5] times, p<0.01). A 22-gauge 
needle was used in 73% (16/22) of the procedures for soft tissue 
and 69% (20/29) of the procedures at other sites (p=0.78). How-
ever, the accuracy of the results of EUS-FNA in the diagnosis 
of recurrence in the soft tissue around a major artery was lower 
than that at other sites. In our study, there were 16 (73%) and 
six (27%) patients with and without a low-echoic mass around 
the artery on EUS imaging. The accuracy of patients with clear 
and unclear low-echoic masses were 81% (13/16) and 67% (4/6), 
respectively (p=0.47). With such a small number of analyses, it 
might be difficult to predict recurrence using EUS images. This 
is a particular problem of EUS-FNA in the diagnosis of recur-
rent cancer. There are several reasons for this result. First, the 
visualization of the soft-tissue area around an artery via EUS 
is sometimes difficult. Second, the stroke range of the FNA 
needles was not sufficient because of tangled vessels, especially 
around the celiac artery. Third, cancer cells can become sparsely 
distributed into the interstices around an artery without forming 
a mass. Thus, to increase the potential for a diagnosis, a differ-
ent approach should be considered for the examination of EUS-
FNA specimens, such as KRAS gene mutation analysis.11,12
Contrast-enhanced CT (CE-CT) and positron emission to-
mography (PET)/CT are currently the most well-established and 
useful tools for restaging patients with suspicion of cancer re-
currence. Kitajima et al.13 reported the diagnostic abilities of CE-
CT and PET/CT for recurrence of pancreatic cancer after surgical 
resection. Forty-five patients, including those with radiological 
imaging follow-up, were analyzed, and the sensitivity, specific-
ity, and accuracy of CE-CT were 66.7% (16/24), 85.7% (18/21), 
and 75.6% (34/45), respectively, whereas those of PET/CT were 
83.3% (20/24), 90.5% (19/21), and 86.7% (39/45), respectively. 
In the 21 patients for whom the final diagnosis was obtained 
from the histopathologic examination, the sensitivity, speci-
ficity, and accuracy of CE-CT were 73.7% (14/19), 50% (1/2), 
and 71.4% (15/21), respectively, while those of PET/CT were 
89.5% (17/19), 50% (1/2), and 85.7% (18/21), respectively. In 
our study, the sensitivity, specificity, and accuracy of EUS-FNA 
were 84% (32/38), 100% (13/13), and 88% (45/51), respectively, 
which are considered sufficient when compared with CE-CT 
and PET/CT, especially in terms of the specificity. There were no 
false-positive cases with EUS-FNA, which is clinically important 
when assessing the recurrence of cancer after surgery. 
For lesion site-based analyses, the sensitivities of CE-CT and 
PET/CT for abdominal lymph node were 62.5% and 75%, and 
those for local recurrence were 50% and 66.7%, respectively. In 
our study, the sensitivity of EUS-FNA for lymph nodes was 93% 
(16/17), while that for local recurrence (soft tissue and remnant 
or margin of the pancreas) was 85% (29/34). The sensitivities of 
EUS-FNA for lymph nodes and local recurrence were sufficient 
compared with CE-CT and PET/CT. PET/CT was limited by the 
need for blood glucose levels to be checked strictly before the 
examination. There is a markedly high incidence of new-onset 
or worsening of diabetes mellitus after pancreatic resection.14 
Magnetic resonance imaging is also useful for detecting local 
recurrence and liver metastasis. Magnetic resonance imaging 
showed a higher sensitivity than PET/CT in the detection of 
liver metastasis; however, its sensitivity for locoregional cancer 
recurrence was low.15
The level of CA19-9 was also used for diagnosing recur-
rence after pancreaticobiliary cancer. We examined the levels of 
CA19-9 at FNA, and the median value was 141 U/mL. Of the 38 
patients with recurrence, only 21 (55%) showed abnormal levels 
of CA19-9. In contrast, of the 13 patients with non-recurrence, 
five (38%) showed abnormal levels of CA19-9 (p=0.30). It is 
therefore difficult to diagnose cancer recurrence using the 
CA19-9 level. EUS-FNA is not necessary in patients with obvi-
ous recurrence, such as liver metastasis or malignant ascites, 
so we excluded these patients. When we are unable to make a 
diagnosis with confidence based on radiographic images, we 
can obtain a definitive diagnosis of recurrence using EUS-FNA, 
allowing treatment for recurrence to be started at an early stage. 
This study was associated with some limitations. First, it em-
ployed a retrospective, single center design, and the number of 
patients with recurrent biliary cancer was small. Second, the 
procedures were only performed when we considered EUS-FNA 
feasible based on radiographic images. Thus, the diagnostic abil-
ity, including the success rate of EUS-FNA, was not evaluated 
correctly. However, 92% (23/25) of cases with soft tissue around 
the artery, which was considered difficult to puncture due to its 
location near a main artery or the existence of interrupted ves-
sels or organs along the puncture route, successfully underwent 
EUS-FNA. Third, several types and sizes of needle were used for 
EUS-FNA, and procedures were performed by several examin-
ers. 
In conclusion, we evaluated the diagnostic ability of EUS-
FNA in cases in which recurrent pancreaticobiliary cancer was 
suspected after surgical resection. EUS-FNA is useful for diag-
nosing recurrent cancer, even after pancreaticobiliary surgery. 
However, FNA of the soft tissue around major arteries was sig-
nificantly associated with false-negative results. The results of 
FNA of the soft tissue around major arteries should therefore be 
interpreted with caution, and close clinical follow-up is needed. 
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